Brussels, Belgium – The European Union (EU) has announced it will buy 300 million doses of the vaccine Pfizer and BioNTech are developing against the new type of coronavirus (Covid-19).
EU Commission President Ursula von der Leyen shared the issue on social media after it was announced that the vaccine was more than 90 percent effective against the virus.
“The EU Commission will soon sign contracts with these companies to receive up to 300 million doses of the vaccine,” von der Leyen said, describing the results from clinical trials of the vaccine as “great news.”
Von der Leyen urged everyone to protect each other against the virus until the development phase of the vaccine is over.
The EU has previously signed contracts to buy vaccines with pharmaceutical companies Johnson and Johnson, AstraZeneca and Sanofi-GSK, in addition, CureVac, BioNTech-Pfizer and Moderna announced successful vaccine acquisition talks.
A potential vaccine developed by the German biotech company BioNTech, co-founded by American pharmaceutical company Pfizer and Turkish scientist Prof Dr Uğur Şahin, against Covid-19 was reported to be more than 90 percent effective against the virus. It was announced that the vaccine candidate was tested on 43,538 people in 6 countries, and no serious safety concerns have been raised in the trials so far.